



IPW

# FITCH, EVEN, TABIN & FLANNERY

ATTORNEYS AND COUNSELLORS AT LAW

Established in 1859

SUITE 401L - 1801 K STREET, NW  
WASHINGTON, D.C. 20006-1201

TELEPHONE (202) 419-7000

FACSIMILE (202) 419-7007

## ILLINOIS OFFICE

SUITE 1600 - 120 SOUTH LASALLE STREET, CHICAGO, ILLINOIS 60603-3406  
TELEPHONE (312) 577-7000

## CALIFORNIA OFFICE

SUITE 250 - 9276 SCRANTON ROAD, SAN DIEGO, CA 92121-7708  
TELEPHONE (858) 552-1311

## COLORADO OFFICE

SUITE 213 - 1942 BROADWAY, BOULDER, COLORADO 80302  
TELEPHONE (303) 402-6966

August 5, 2004

EDWARD E. CLAIR  
JON A. BIRMINGHAM  
JOHN E. LYHUS  
STEVEN M. FREELAND  
DONNA E. BECKER  
MICHAEL G. VRANICAR  
BRIAN S. CLISE  
MARTIN R. BADER  
DEREK L. PRESTIN  
MARK A. BORSOS  
DAVID R. JAGLOWSKI  
TIMOTHY R. BAUMANN  
JEFFREY A. CHELSTROM  
NICHOLAS T. PETERS  
KENNETH A. PLOCHINSKI  
MEGAN J. REDMOND

## PATENT AGENTS

ERIC J. WHITESELL  
LILIA I. SAFONOV

## OF COUNSEL

GEORGE W. SPELLMIRE, JR.  
LISA M. SOMMER  
GEORGE H. SPENCER, P.C.\*

## TECHNICAL ADVISOR

JOHN M. BRONK, PH.D.

\*ADMITTED TO D.C. BAR; D.C. PRACTICE OF  
ALL OTHERS LIMITED TO FEDERAL COURTS  
AND AGENCIES

MORGAN E. FITCH, JR.  
FRANCIS A. TABIN  
JULIUS TABIN  
JOHN F. FLANNERY  
ROBERT B. JONES  
JAMES J. SCHUMANN  
JAMES J. HAMILL  
TIMOTHY E. LEVSTIK  
JOSEPH E. SHIPLEY  
KENNETH H. SAMPLES  
PHILIP T. PETTI  
JOSEPH T. NABOR  
STEVEN C. SCHROER  
RICHARD A. KABA\*  
KARL R. FINK  
MARK W. HETZLER  
TIMOTHY P. MALONEY  
JAMES P. KRUEGER  
STEPHEN S. FAVAKEH  
RICHARD E. WAWRZYNIAK  
STEVEN G. PARMELEE  
THOMAS F. LEBENS  
BRUCE R. MANSFIELD  
KENDREW H. COLTON\*  
G. PAUL EDGE\*  
MICHAEL A. SANZO\*  
SCOTT A. MENGHINI  
NORMAN N. KUNITZ\*  
RUDY KRATZ  
RAMON R. HOCH\*

Commissioner of Patents  
U.S. Patent and Trademark Office  
220 20<sup>th</sup> Street South  
Customer Window, MS Reissue  
Crystal Plaza Two, Lobby, Room 1B03  
Arlington, VA 22202

Re: Second Supplemental Information Disclosure Statement  
Appl. No.: 10/811,793  
Filed: March 29, 2004  
Title: Treatment of Migraine Headache  
Inventor(s): Plachetka, *et al.*  
Atty. Dkt.: 7569/80993

Dear Sir:

The following documents are being forwarded for appropriate action by the U.S. Patent and Trademark Office:

1. Second Supplemental Information Disclosure Statement;
2. PTO Form-1449, List of References Cited by Applicant;
3. Reference AL1; and
4. Return postcard.

Applicants do not believe that any fee is due for the filing of this Information Disclosure Statement. However, the Director is hereby authorized to charge any fee deficiency with respect to this filing and any other fee required in connection with the present case, or credit any overpayment, to our Deposit Account No. 06-1135 under Order No. 7569/80993.

Commissioner for Patents  
August 5, 2004  
Page 2

It is respectfully requested that the enclosed postcard be stamped with the date the enclosed documents are received by the PTO and that it be returned as soon as possible.

Very truly yours,

FITCH, EVEN, TABIN & FLANNERY



Michael A. Sanzo  
Reg. No. 36,912  
Attorney for Applicants

MAS:ct  
Enclosures



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re reissue patent application of:

Plachetka, *et al.*

Appl. No.: 10/811,793

Filed: March 29, 2004

For: **Treatment of Migraine Headache**

Art Unit: to be assigned

Examiner: to be assigned

Atty. Dkt.: 7569/80993

**Second Supplemental Information Disclosure Statement**

Commissioner of Patents  
U.S. Patent and Trademark Office  
220 20<sup>th</sup> Street South  
**Customer Window, MS Reissue**  
Crystal Plaza Two, Lobby, Room 1B03  
Arlington, VA 22202

Sir:

Submitted herewith is a listing of documents known to Applicants and/or their attorney in compliance with the requirements of 37 C.F.R. § 1.56. Copies of the listed documents are also enclosed.

The document listed on the enclosed List of References is a Press Release indicating that the FDA did not approve Pozen's MT 100 product, which is a preparation containing naproxen sodium and metoclopramide. Applicants are continuing to work with the FDA to resolve the issues raised in their non-approval letter.

Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the present application. This statement should not be construed as a representation that more material information does not exist or that an exhaustive search of the relevant art has been made.

Consideration of the cited documents and making the same of record in the prosecution of the above-captioned application are respectfully requested.

Applicants do not believe that any fee is due for the filing of this Information Disclosure Statement. However, the Commissioner is hereby authorized to charge any fee deficiency to our Deposit Account No. 06-1135 under Order No. 7569/80993.

Respectfully submitted,

FITCH, EVEN, TABIN & FLANNERY

By \_\_\_\_\_


*Michael A. Sanzo*

Michael A. Sanzo

Reg. No. 36,912

Attorney for Applicants

Date August 5, 2004  
1801 K Street, N.W., Suite 401L  
Washington, DC 20006-1201  
Phone: (202) 419-7013

	Atty. Docket No.: 7569/80993		Appl No.: 10/811,793
	Applicant(s) Plachetka, et al.		
	Filing Date: March 29, 2004		Group: to be assigned

#### U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	AA 1						
	AB 1						
	AC 1						
	AD 1						
	AE 1						
	AF 1						
	AG 1						

#### FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	AH 1							
	AI 1							
	AJ 1							
	AK 1							

#### OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AL 1	Copy of Press Release indicating Non-Approval of MT 100 Product of Pozen.
	AM 1	
	AN 1	
	AO 1	
	AP 1	
	AQ 1	
	AR 1	
	AS 1	

Examiner	Date Considered
----------	-----------------